PharmiWeb

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the ...

Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response –OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd.
PharmiWeb

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), ...
PharmiWebOpinion

Biden's DEA Wall of Marijuana Dishonor: The DEA Pattern of Corruption Is Now Impossible to Deny, President Trump Fixing

Now, President Trump is poised to fix the marijuana rescheduling issue.From DEA unconstitutional tribunals to Anne Milgram ...
PharmiWeb

Salubris Biotherapeutics Announces Dose Escalation Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology 2025 Congress

(PRs) among 13 evaluable non-small cell lung cancer (NSCLC) patients (ORR 38%); 1 confirmed PR among 7 breast cancer patientsFavorable safety and PK profile, with encouraging activity, demonstrate a ...
PharmiWeb

Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated ...
PharmiWeb

Sensient Announces Conference Call

Sensient Technologies Corporation (NYSE: SXT) will hold its earnings call and webcast to discuss 2025 third quarter results at 8:30 a.m. CDT on Friday, October 31, 2025. Investors may access the live ...
PharmiWeb

Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential ...
PharmiWeb

UniDoc Announces Amended LIFE Offering

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / October 17, 2025 / UniDoc Health Corp.
PharmiWeb

Desert Oasis Healthcare and RadNet Partner to Advance Early Breast Cancer Detection

Program will increase access to cutting-edge AI-powered breast cancer detection and is designed to boost compliance with annual cancer-screening guidelines PALM SPRINGS, CALIFORNIA / ACCESS Newswire / ...
PharmiWeb

MLTX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The law firm of Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Bridgewood v. MoonLake Immunotherapeutics, No. 25-cv-08500 (S.D.N.Y.) – seeks to represent ...
PharmiWeb

Roseman University of Health Sciences Dedicates the Thorne Clinic for Integrative Oral Health and Primary Care

Roseman University of Health Sciences and PDS Health® celebrated the dedication and ribbon-cutting of the new Thorne Clinic ...
PharmiWeb

Psyence Group Inc. Announces RSU Grants

TORONTO, ON / ACCESS Newswire / October 17, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), announces that it granted an aggregate of 721,448 restricted share units (each an "RSU") ...